TRUSOPT Eye drops, solution Ref.[8489] Active ingredients: Dorzolamide

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2023  Publisher: Santen Oy, Niittyhaankatu 20, 33720, Tampere, Finland

Product name and form

TRUSOPT 20 mg/ml eye drops, solution.

Pharmaceutical Form

Eye drops, solution.

Clear, colourless to nearly colourless, slightly viscous, solution.

Qualitative and quantitative composition

Each ml contains 22.26 mg of dorzolamide hydrochloride equivalent to 20 mg of dorzolamide.

Excipient with known effect: One ml of eye drops solution contains 0.075 mg benzalkonium chloride and one drop contains about 0.002 mg of benzalkonium chloride.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Dorzolamide

Dorzolamide is a potent inhibitor of human carbonic anhydrase II. Following topical ocular administration, dorzolamide reduces elevated intra-ocular pressure, whether or not associated with glaucoma.

List of Excipients

Benzalkonium chloride
Hydroxyethylcellulose
Mannitol (E421)
Sodium citrate (E331)
Sodium hydroxide (E524) for pH adjustment
Water for injections

Pack sizes and marketing

TRUSOPT container contains 5 ml of solution. Two alternate containers may be marketed.

White translucent low-density polyethylene (LDPE) container with a transparent linear LDPE dropper tip and a white polypropylene (PP) cap or OCUMETER Plus Ophthalmic Dispenser consists of a translucent, high-density polyethylene container with a sealed dropper tip, a flexible fluted side area which is depressed to dispense the drops, and a 2-piece cap assembly. The 2-piece cap mechanism punctures the sealed dropper tip upon initial use, then locks together to provide a single cap during the usage period. Tamper evidence is provided by a safety strip on the container label.

TRUSOPT is available in the following packaging configurations:

1 × 5 ml (single 5-ml container)

3 × 5 ml (three 5-ml containers)

6 × 5 ml (six 5-ml containers)

Not all pack sizes may be marketed.

Marketing authorization holder

Santen Oy, Niittyhaankatu 20, 33720, Tampere, Finland

Marketing authorization dates and numbers

PL 16058/0014

Date of first authorisation: 09 January 1995
Date of latest renewal: 11 November 2009

Drugs

Drug Countries
TRUSOPT Austria, Australia, Brazil, Canada, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Malta, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.